ANALYSIS OF THE QUALITY OF PHARMACOLOGY AND ITS COMPLIANCE WITH CURRENT CLINICAL GUIDELINES IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
Abstract
Ischemic heart disease (IHD) remains one of the leading causes of morbidity and mortality, which determines the high importance of optimal and evidence-based pharmacotherapy. The present study aimed to analyze the quality of pharmacotherapy in patients with stable IHD and to assess its compliance with current clinical guidelines. A retrospective evaluation of prescribed medications was performed, taking into account their drug classes, dosages and combinations, as well as the frequency of use of the main groups of drugs recommended for the treatment of stable IHD. The obtained results made it possible to determine the degree of adherence to contemporary clinical guidelines and patient compliance with prescribed therapy. The analysis highlights the need for regular monitoring of pharmacotherapy quality and for improving physicians' adherence to contemporary clinical guidelines in order to enhance prognosis and quality of life in patients with stable IHD.
References
1. Stark Benjamin, Johnson Catherine, Andrew Roth Gregory. Global prevalence of coronary artery disease: an update from the global burden of disease study. Journal of the American College of Cardiology.2024;83(13): 2320-2320.
2. Ralapanawa U, Sivakanesan R. Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review. J Epidemiol Glob Health. 2021;11(2):169-177.
3. Suyarov Sh.M. Risk factors for the development of ischemic heart disease in Uzbekistan: current state and ways of improvement. Eurasian Journal of Medical and Natural Sciences. 2025;5(3):99–101. [Russian: Суярoв Ш.М. Факторы риска развития ишемической болезни сердца в Узбекистане: современное состояние и пути решения. Eurasian Journal of Medical and Natural Sciences. 2025;5(3):99–101].
4. Barbarash O.L., Karpov Yu.A., Panov A.V., et al. Stable ischemic heart disease. Clinical guidelines 2024. Russian Journal of Cardiology. 2024;29(9):6110. [Russian: Барбараш О.Л., Карпов Ю.А., Панов А.В. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110].
5. Christiaan Vrints , Felicita Andreotti , Konstantinos C Koskinas et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery. European Heart Journal, 2024;45(36): 3415–3537. https://doi.org/10.1093/eurheartj/ehae177.
6. Virani SS, Newby LK, Arnold S et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148(9):9-119.
7. Galli Mattia, Cortellini Gabriele, Occhipinti Giovanni. Aspirin Hypersensitivity in Patients With Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology. 2024;84(18):1748-1766.
8. Russo Isabella, Griffith Carola, Barale Cristina. Current strategies to guide the antiplatelet therapy in acute coronary syndromes. International journal of molecular sciences. 2024;25(7):3981; https://doi.org/10.3390/ijms25073981.
9. Dorodnykh I.A., Mal G.S. Pharmacological response to statins in the treatment of ischemic heart disease. Scientific Interdisciplinary Research. 2022:494–496. [Russian: Дородных И.А., Маль Г.С. Лекарственный ответ статинов при лечении ИБС. Научные междисциплинарные исследования. 2022:494–496].
10. Sung-Jin Hong, Yong-Joon Lee, Seung-Jun Lee. Treat-to-target or high-intensity statin in patients with coronary artery disease. JAMA. 2023;329:(13):1078-1087. doi:10.1001/jama.2023.2487.
11. Vasiliev A.P., Streltsova N.N. Development of antianginal pharmacotherapy from a historical perspective: from theoretical premises to practical outcomes. Meditsinskii Sovet. 2022;16(17):27–33. https://doi.org/10.21518/2079-701X-2022-16-17-27-33 [Russian: Васильев А.П., Стрельцова Н.Н. Формирование антиангинальной фармакотерапии в историческом аспекте. От теоретических предпосылок к практическому эффекту. Медицинский совет. 2022;16(17):27–33].
12. Gurevich M.A., Kuzmenko N.A. Use of ivabradine in the rational treatment of ischemic heart disease. Systemic Hypertension. 2016;13(4):26–29. [Russian: Гуревич М.А., Кузьменко Н.А. Использование ивабрадина в рациональном лечении ишемической болезни сердца. Системные гипертензии. 2016;13(4):26–29].
13. Ministry of Health of the Republic of Uzbekistan. Clinical protocols and standards of the Republic of Uzbekistan for the diagnosis and treatment of stable angina. Tashkent; 2024. Available at: https://gov.uz/ru/ssv/pages/klinik-qo-llanmala [Russian: Клинические протоколы и стандарты Республики Узбекистан по диагностике и лечению стабильной стенокардии. — Минздрав Республики Узбекистан, 2024].
14. Naumova E.A., Semenova O.N. A modern view on the problem of patient adherence to long-term therapy. Cardiology: News, Opinions, Education. 2016;2:30–39. [Russian: Наумова Е.А., Семенова О.Н. Современный взгляд на проблему приверженности пациентов к длительному лечению. Кардиология: новости, мнения, обучение. 2016;2:30–39].
15. Jones Laney K., East Cara, Ganda Om P. Adherence to Lipid‐Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta‐Analysis. Journal of the American Heart Association. 2025;14(17): :e037530.https://doi.org/10.1161/JAHA.124.037530
